CytoSite Biopharma
Sudbury
About CytoSite Biopharma
CytoSite Biopharma is a biotechnology start-up developing a new technology to predict and monitor response to Immuno-Oncology therapy. The company develops a novel and proprietary small molecule PET imaging probe that will enable clinicians to predict early in the treatment cycle which patients will respond to I-O therapy. It was founded by James Jenson in 2016 and is based in Sudbury, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $7.5M
- Last round: Series Unknown (Sep 2019)
- Website: cytositebiopharma.net
- Phone: +1 978-460-0695
Industries & Categories
Biotechnology, Oncology
Canonical: https://fsome.com/organization/cytosite-biopharma-113410 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.